EGFR and neoplasm: This newly engineered CAR, designated CAR-TEAM, can produce TEAM (T-cell Engaging Antibody Molecule) that targets wild type EGFR, and like BiTE, binds both EGFR on the tumor cells at the local site and CD3 on the T cells.